Cerebrospinal fluid (CSF) is virtually the only one accessible source of proteins derived from the central nervous system (CNS) of living humans and possibly reflects the pathophysiology of a variety of neuropsychiatric diseases. However, little is known regarding the genetic basis of variation in protein levels of human CSF. We examined CSF levels of 1,126 proteins in 133 subjects and performed a genome-wide association analysis of 514,227 single nucleotide polymorphisms (SNPs) to detect protein quantitative trait loci (pQTLs). To be conservative, Spearman's correlation was used to identify an association between genotypes of SNPs and protein levels. A total of 421 cis and 25 trans SNP-protein pairs were significantly correlated at a false discovery rate (FDR) of less than 0.01 (nominal P < 7.66 Â 10
Introduction
Advances in high-throughput experimental techniques have enabled genome-wide association analysis of gene expression quantitative trait loci (eQTLs) in humans using various kinds of cells and tissues (1) (2) (3) . We previously reported the results on genome-wide investigations of SNPs affecting the expression levels in whole blood (3) . Findings from these studies show that genetic factors account for a large proportion of the variation in human gene expression. The cis-eQTLs, which are located in the vicinity of their gene of origin, generally have stronger effects on gene expression than trans-eQTLs, which are located far from the gene, often on different chromosomes. Previous evidence indicates that trait-associated single nucleotide polymorphisms (SNPs) are more likely to be eQTLs than other randomly chosen SNPs (4) . Therefore, the discovery of SNPs influencing gene expression may have a large impact on future biomarker studies.
Many regulatory mechanisms occur after mRNAs are produced. Protein levels are regulated post-transcriptionally by mechanisms such as 5' capping, 3' polyadenylation, pre-mRNA splicing, and mRNA degradation and translation suppression by miRNAs. Previous studies in various organisms have shown that approximately only 40% of the variation in protein concentration is explained by mRNA abundances (5) . Therefore, available database from eQTL studies is not sufficient to predict the relationship between genetic variation and protein expression. Proteins have more direct influence on trait variation compared to mRNAs, and therefore, examining the relationship between genetic variants and proteome may provide new biological insights and biomarkers.
eQTL studies using post-mortem brains have identified a number of SNPs regulating mRNA expressions in human brains (6) . However, little is known regarding the genetic basis of variation in protein levels in the human central nervous system (CNS). Cerebrospinal fluid (CSF) is virtually the only one accessible source of proteins derived from CNS of living humans that are used as biomarkers for a variety of neurological disorders. Kauwe et al. (7) reported genetic associations with CSF levels of several proteins involved in amyloid processing and inflammation, suggesting that genetic variations play an important role in the regulation of CSF proteins and the pathophysiological mechanisms of neurological disorders.
Recent studies have examined the genome-wide association between human genetic variation and protein abundance to identify protein quantitative trait loci (pQTL) in lymphoblastoid cell lines (8, 9) . To our knowledge, however, no previous studies have examined the association between genetic polymorphisms and in vivo levels of protein expression in the human CNS at genome-wide and proteome-wide levels. The aim of the present study was to identify SNPs that are associated with protein levels in the human CSF. We expected that pQTL analysis will reflect post-transcriptional regulatory mechanisms in the CNS that are not captured in previous eQTL studies. We examined the CSF levels of 1,126 proteins detected by the aptamerbased proteomics (SOMAscan) in 133 physically healthy Japanese individuals and performed a genome-wide association analysis of 514,227 SNPs to detect CSF pQTLs.
Results
CSF levels of 1,126 proteins and 514,227 SNPs which had passed quality control as described in Materials and Methods section were used for further analysis. Significant SNPs were defined as cis-pQTLs if the distance between the SNP chromosomal position and the gene encoding the protein was 1 Mb or less. Conversely, significant SNPs were defined as trans-pQTLs if the gene encoding the protein was on a different chromosome or was located more than 1Mb away from the SNP.
Comparison between linear regression analysis and Spearman's correlation analysis
The correlation between SNP genotypes and protein expression was first assessed using both linear regression model and Spearman's correlation coefficient (q) test between the number of minor alleles (0, 1, or 2) for a given SNP and the CSF levels of the associated protein. As shown in Figure 1 , linear regression analysis revealed 4,412 significant SNP-protein pairs with false discovery rate (FDR) < 0.01 (nominal P < 7.62 Â 10
À8
); however, among them 2,576 pairs (58.4%) were not significant at a level of nominal P ¼ 0.05 when analysed by Spearman's correlation. On the other hand, only 19 (4.3%) of the 446 SNP-protein pairs with FDR < 0.01 (nominal P < 7.66 Â 10 À9 ) by Spearman's correlation analysis were not significant at a level of nominal P ¼ 0.05 when analysed by linear regression. As in the examples shown in Supplementary Materials, Figures S1 and S2, linear regression analysis is susceptible to the effects of outliers, and the coincidence of rare homozygous alleles and rare high or low protein expression levels can result in spurious correlations. Therefore, to avoid false findings, nonparametric Spearman's correlation coefficient test, which is less prone to the influence of outliers, was used to establish a significance threshold for pQTLs in the present study.
Identification of pQTL SNP-protein pairs
We identified 446 significant pQTL SNP-protein pairs (consisting of 391 SNPs and 65 proteins) with FDR < 0.01 (jqj > 0.462, nominal P < 7.66 Â 10
À9
), as shown in Supplementary Material, Table S1 . Table 1 lists the top pQTL SNPs for each significant protein. Figure 2 shows the quantile-quantile (QQ) plot of the P values from the analysis. Of the 446 significant SNP-protein pairs, 421 were cis-SNP-protein pairs (372 SNPs and 55 proteins), and 25 were trans-SNP-protein pairs (25 SNPs and 10 proteins). Because subjects included 88 patients with psychiatric diagnosis, we next calculated Spearman's q of the significant 446 pQTL SNPprotein pairs for psychiatric patients and psychiatrically healthy subjects separately to examine whether psychiatric diagnosis influenced SNP-protein associations. As shown in Supplementary Materials, Figure S3 , pQTL SNP-protein pairs were strongly correlated even when patients and healthy subjects were analysed separately.
In order to increase the power to detect cis-pQTLs, we also performed cis-only analysis by examining only SNPs located within 1Mb of the gene encoding the targeted protein. Cis Figure 3 shows the QQ plot of the P values from the cis-only analysis, and the Manhattan plot of genome-wide distribution of cis-pQTLs is shown in Figure 4 . Spearman's q of significant cis-pQTL SNP-protein pairs calculated separately for psychiatric patients and psychiatrically healthy subjects, as shown in Supplementary Material, Figure  S4 , indicated that most of the cis-pQTL SNP-protein pairs were strongly correlated even when patients and healthy subjects were analysed separately.
The distribution of FDR values in our SNP-protein correlation analyses are shown in Supplementary Material, Figure S5 . The histograms indicate that a relatively large proportion of SNPprotein pairs fall within the significance criteria of FDR < 0.01.
Overlap between CSF pQTLs and disease/traitassociated SNPs
We examined whether pQTL SNPs tend to be associated with a particular disease or trait. The catalogue of published genomewide association studies (GWAS) provided by National Human Genome Research Institute (NHGRI) (10) was used to select disease/trait-associated SNPs at a threshold of P < 10 À5 in previous GWAS. Of the 514,227 SNPs examined in the present study, 7,655 SNPs, of which 28 were pQTL SNPs, were identified in the NHGRI database as disease/trait-associated. The percentages of disease/trait-associated SNPs were significantly higher for pQTL SNPs than for non-pQTL SNPs (pQTL SNPs: 7.14%, non-pQTL SNPs: 1.48%, v 2 ¼ 85.5, P < 2.29 Â 10
À20
). pQTL SNPs were 4.8 (95% confidence interval (95% CI): 3.4-6.9) times more likely to be disease/trait-associated than non-pQTL SNPs. Table 2 shows the list of 28 disease/trait-associated CSF pQTL SNPs.
Comparison with a blood pQTL study
We compared our findings with previously identified cis-pQTLs associated with protein expression in blood at an FDR threshold < 0.05 according to a study by Lourdusamy et al. (9) . Of the 60 proteins with pQTLs reported by Lourdusamy et al. (59) were included in our cis-analysis. The percentage of proteins with cispQTLs identified in the present study was significantly higher in proteins with reported blood cis-pQTLs than in proteins without reported blood cis-pQTLs (33.9% in proteins with blood cis-pQTLs and 8.5% in proteins without blood cis-pQTLs, v 2 ¼ 40.76,
). Some pQTL SNPs acted as both CSF and blood pQTLs for the same protein. Such SNPs were identified for 13 proteins in the present study, which are shown in Supplementary Material, Table S4 . Notably, all these 13 SNPs had the same direction of allelic effect on CSF and blood protein levels.
Comparison with previous brain eQTL studies
We compared our findings with previously identified eQTLs associated with gene expression in the brain at a FDR with previously reported brain eQTL SNPs. A total of 70 brain eQTL SNPs meeting the following conditions were selected: (1) included in our SNP typing data or in LD (r 2 > 0.5) with at least one of the SNPs in our SNP typing data; (2) significantly associated with the expression level of a gene that encodes a protein included in our analysis. We examined the association between the brain eQTL SNPs and CSF levels of the protein encoded by the target gene of the eQTL SNP. For brain eQTL SNPs not included in our SNP typing data, a surrogate SNP in strongest LD (r 2 > 0.5) was used for examining association with the CSF protein level. As a result, we found that 24% of the brain eQTL SNPs or surrogate SNPs were significantly correlated with the CSF levels of the protein encoded by the gene at nominal P < 0.05 (Supplementary Material, Table S3 ).
Discussion
To our knowledge, this study provides the first genome-wide and proteome-wide assessment of pQTLs that correlate with protein expression levels in the CSF. We identified approximately 6% of the examined proteins that were significantly associated with pQTL SNPs at a significance level of FDR < 0.01. The results showed that most of the genetic regulation of human CSF protein levels by common variants was caused by cis effects. Cis-only analysis identified approximately 10% of the examined proteins that were significantly associated with cispQTL SNPs at a significance level of FDR < 0.01. The present findings suggest that a substantial proportion of CSF proteins are regulated by common genetic variants. A linear regression model is commonly employed in eQTL and pQTL studies to determine significant correlations between SNP genotypes and expression levels. However, our results showed that linear regression analysis resulted in a large number of false positive as well as some false negative correlations. The undesirable effects of rare high or low expression values must be eliminated or controlled in order to achieve reliable results when applying linear regression. To avoid reporting spurious correlations due to outliers, Spearman's correlation analysis was used in the present study to detect correlated SNP-protein pairs. Many of the highly correlated CSF pQTLs reported in this study have been previously reported to be associated with protein levels in blood. Consistent with the present findings, our previous ELISA-based studies showed that blood levels of resistin and soluble interleukin-6 receptor (IL-6R) were strongly correlated with rs3219175 of RETN gene and rs8192284 of IL6R gene, respectively (12, 13) . When compared with the genome-wide pQTL studies which examined protein levels in human plasma (9) , CSF cis-pQTLs were identified for more than 1/3 of the proteins that were associated with previously identified plasma cispQTLs, indicating that a number of pQTL variants correlate with protein levels in both CSF and blood. This is not surprising as a substantial proportion of CSF proteins originates from blood, and therefore, may be dependent on the blood levels. However, the levels of the proteins that do not cross the blood-brain barrier may be independently regulated in peripheral tissues and brain by pQTL variants. This view is supported by the evidence from previous eQTL studies (14, 15) that transcriptome organization is preserved between brain and blood to some extent. On the other hand, many of the proteins identified as CSF pQTLs in the present study had not been previously identified as blood pQTLs (9, 16) . The presence of such pQTLs may indicate that some genetic variants function to regulate protein levels in the CNS but not in the peripheral tissues. The rate of protein secretion from brain cells as well as loss by absorption to tissue and transport into blood also influence CSF protein abundance. Such factors may have contributed to the inconsistency in pQTL effects between CSF and blood.
Elucidation of proteins correlated with SNPs will allow us to better understand the biology underlying the traits and diseases identified in a number of GWAS. As expected, our results showed that CSF pQTLs were more likely than non-pQTLs to be trait/disease-associated SNPs. This finding suggests that many of the trait/disease-associated SNPs exert influence on the risk of developing a particular trait/disease by altering the protein levels. If the protein-regulating function of the diseaseassociated SNP is responsible for the development of the disease, the target protein may serve as a more sensitive biomarker of the disease than the associated SNP. In this respect, pQTL studies reveal valuable information, when combined with GWAS findings, for the development of effective biomarkers. CSF is a potential source of biomarkers for various disorders of the CNS. Our results may have revealed new protein biomarkers relevant to the pathophysiology of diseases. The present findings will be an important resource for future discovery of novel CSF biomarkers.
To date, few data exist on the relationship between genetic variants and CSF protein levels. A recent study by Kauwe et al. (7) examined the genome-wide association of CSF levels of 59 Alzheimer's disease candidate proteins and identified genetic associations with CSF levels of 5 proteins (angiotensin-converting enzyme, C-C motif ligand 2, C-C motif ligand 4, IL-6R, and matrix metalloproteinase-3 (MMP3)). Of these 5 proteins, C-C motif ligand 2, IL-6R, and MMP3 were included in the analyses of the present study. Consistent with Kauwe et al., our results showed that the C allele of IL6R rs2228145 was associated with increased levels of IL-6R (q ¼ 0.78, nominal P ¼ 7.3 Â 10
À29
) and that the A allele of MMP3 rs645419 was associated with increased levels of MMP3 (q ¼ 0.25, nominal P ¼ 0.003). The association of rs2228467 with the CSF level of C-C motif ligand 2, which was identified by Kauwe et al., could not be examined in the present study, because our GWAS platform did not include rs2228467 or any SNPs in strong LD with rs2228467. To our knowledge, no other studies have extensively examined the association between SNPs and CSF protein levels in humans, and thus, our results provide a wealth of novel findings on the relationship between genetic variants and CSF proteins.
A limitation of the present study was that we could not control for covariates that may influence the protein levels of CSF. For example, the collection time of day and fasting time before sampling may influence the levels of some proteins. Future studies should take into account environmental and technical factors that may influence the protein levels. Despite the limitation, however, we believe that the results of our statistical analysis are robust enough to support the finding that genetic variations play a role in the regulation of CSF proteins. Another limitation was that we could not investigate any functional or structural features that are characteristic of the proteins. There may be a functional or structural difference between proteins with tissue-shared pQTLs and proteins with tissue-specific pQTLs. Future studies should simultaneously examine protein levels in CSF and other tissues to understand factors that distinguish tissue-specific from tissue-shared pQTLs.
In summary, we present, for the first time, results of genome-and proteome-wide investigations of associations between SNP genotypes and protein levels in the CSF of humans, providing a catalogue of hundreds of SNP-protein pairs that showed a significant correlation even after correcting for multiple testing. pQTLs identified in this study may be potential candidates for genetic variations associated with human traits and diseases and will provide clues for interpreting genotypephenotype association identified in GWAS. We believe that our new data may serve as a valuable resource for future neuropsychiatric research.
Materials and Methods

Study participants
Study participants were recruited through advertisements in free local information magazines and by our website announcement and from the outpatient clinic of the National Center Hospital, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan. Subjects consisted of 68 men and 65 women with a mean age (standard deviation) of 42.2 (11.7) years. Most of them participated in our previous studies (17) (18) (19) , one of the aims of which was to examine the CSF protein levels of patients with psychiatric disorders. Therefore, 66% of the subjects were diagnosed with a psychiatric disorder (28 patients with schizophrenia, 15 with bipolar disorder, and 45 with depressive disorder). Antipsychotic medication was prescribed in 61% of patients with schizophrenia, 40% of patients with bipolar disorder, and 22% of patients with depressive disorder. Antidepressant medication was prescribed in 14% of patients with schizophrenia, 20% of patients with bipolar disorder, and 38% of patients with depressive disorder. Furthermore, 33% of patients with bipolar disorder were prescribed mood stabilizers including lithium, lamotrigine, and valproate. All participants were physically healthy and without clinically significant systemic disease (e.g., malignant disease, diabetes mellitus, renal failure, or endocrine disorders), based on self-reports, at the time of assessment. Participants were excluded if they had a prior medical history of CNS disease or severe head injury, or if they met Diagnostic and Statistical Manual of Mental Disorders fourth edition (DSM-IV) (20) criteria for mental retardation, substance dependence, or substance abuse. All subjects were biologically unrelated Japanese individuals who resided in the Western part of Tokyo. The study protocol was approved by the ethics committee at the National Center of Neurology and Psychiatry, Japan. After a description of the study, written informed consent was obtained from every subject. The SNP and protein data from this study can be accessed at NCBI Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo; date last accessed November 3, 2016) under accession number GSE83711.
Laboratory methods
Non-fasting CSF was drawn between 1000 h and 1600 h (mean 1311 h) from the L4-L5 or L3-L4 interspace, with the subject in the left decubitus position. CSF samples were collected between May, 2010 and February, 2014 at the National Center Hospital, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan. The samples were transferred on ice immediately after collection, centrifuged at 4000 Â g, aliquoted, and stored at À80 C until they were assayed.
Genome-wide SNP typing
Genomic DNA was prepared from venous blood according to standard procedures. Genotypes were examined using the Illumina HumanOmni1-Quad BeadChip (Illumina, Inc., San Diego). A total of 954,703 SNPs were assessed for quality using the PLINK v1.07 software (21) . All SNPs with a call rate below 90%, a deviation from Hardy-Weinberg equilibrium at an error level of P < 0.001, or a minor allele frequency of less than 5% were excluded, and duplicated SNPs were removed. The remaining 514,227 SNPs were used for subsequent analyses. The overall missing rate in the SNP typing data of 514,227 SNPs was 0.035%. The minimum call rate for SNPs and samples were 98.5% and 99.6%, respectively.
Measurement of proteins
Workers at SomaLogic Inc. (Boulder, CO) who were blind to the subject characteristics, performed the proteomic assessments as described elsewhere (22, 23) . The assay consists of equilibrium binding of fluorophore-tagged SOMAmers and proteins in CSF and automated partitioning steps to capture only the SOMAmers that are in complexes with their cognate proteins. The assay transforms the measurement of proteins into the measurement of the corresponding SOMAmers (DNA) via hybridization to an antisense probe array. Normalization and interrun calibration were performed as described elsewhere (24) . In brief, correction for systematic effects on the data introduced during the hybridization step, median normalization within an array, and calibration between the plates were performed. Concentrations of 1,128 proteins were reported in relative fluorescence units (RFU) after normalization and calibration. All examined proteins were successfully measured in all subjects. The mean and median intra-assay coefficients of variation for calibrator samples were 7.0% and 5.0%, respectively. The mean and median inter-assay coefficients of variation for calibrator samples were 3.4% and 2.5%, respectively.
A total of 1,126 proteins, excluding HIV-2 Rev and C34 gp41 HIV Fragment, were used for the analyses.
Statistical analysis
All statistical analyses were performed using R software version 3.2.3 (25) . Linear regression analysis between the number of minor alleles in each SNP and CSF levels of each protein was performed using the MatrixEQTL package (26). Spearman's correlation coefficient test was used to establish a significance threshold for pQTLs. Spearman's correlation analysis was considered significant at FDR < 0.01. FDR was calculated according to Benjamin and Hochberg's method. Manhattan plot was displayed using the qqman package (27) .
